(PRME) Prime Medicine Common - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74168J1016
PRME: Genetic, Therapies, Editing, DNA, Proteins, Enzymes
Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company specializing in gene editing therapies to treat a wide range of diseases. Its proprietary Prime Editing platform combines a Cas protein and a reverse transcriptase enzyme to enable precise DNA edits. The system uses pegRNA to guide the Prime Editor protein to specific genomic locations and provides a template for targeted DNA modifications. This approach aims to address both monogenic and complex diseases with higher specificity and efficiency compared to traditional gene editing tools.
The company has established strategic collaborations to advance its pipeline. Its partnership with Cimeio Therapeutics focuses on developing Prime Edited Shielded-Cell & Immunotherapy Pairs (SCIPs) for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Additionally, Prime Medicine has a research collaboration and license agreement with Bristol Myers Squibb to develop and commercialize multiple prime edited ex vivo T-cell therapies, expanding its reach in immuno-oncology.
Founded in 2019 and headquartered in Cambridge, Massachusetts, Prime Medicine operates at the forefront of gene editing innovation. Its platform has shown promise in preclinical studies, positioning the company as a key player in the genetic therapy landscape. For more information, visit: https://primemedicine.com.
Based on
Technically, PRME is trading below its SMA 20 and SMA 50, indicating bearish momentum. The stock price of $2.42 is significantly below its SMA 200 of $4.28, suggesting long-term weakness. ATR of $0.24 indicates moderate volatility, with potential price swings of ±$0.24-$0.48 in the near term. Average volume of 1.08M shares suggests limited liquidity, which could amplify price movements.
Fundamentally, PRMEs market cap of $388.89M reflects a speculative valuation, with a P/S ratio of 486.12 indicating high expectations for future revenue growth. The P/B ratio of 2.05 suggests investors are pricing in potential upside from its gene editing platform. However, the lack of profitability (P/E: 0.00) and return on equity (RoE: None) highlights the companys early-stage nature and reliance on R&D advancements.
Forecast: PRME is likely to remain volatile, with potential downside risk due to its technical weakness and speculative valuation. Short-term support may emerge near $2.00, while resistance could be met at $3.00. Investors should monitor clinical trial progress and partnership developments for potential catalysts.
Additional Sources for PRME Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PRME Stock Overview
| Market Cap in USD | 249m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2022-10-20 |
PRME Stock Ratings
| Growth 5y | -68.4% |
| Fundamental | -14.3% |
| Dividend | 0.0% |
| Rel. Strength Industry | -71.9 |
| Analysts | 4.5/5 |
| Fair Price Momentum | 0.98 USD |
| Fair Price DCF | - |
PRME Dividends
No Dividends PaidPRME Growth Ratios
| Growth Correlation 3m | -63% |
| Growth Correlation 12m | -92.7% |
| Growth Correlation 5y | -96.5% |
| CAGR 5y | -59.26% |
| CAGR/Max DD 5y | -0.65 |
| Sharpe Ratio 12m | -2.05 |
| Alpha | -98.25 |
| Beta | 3.09 |
| Volatility | 93.57% |
| Current Volume | 877.6k |
| Average Volume 20d | 1264k |
As of March 15, 2025, the stock is trading at USD 1.79 with a total of 877,612 shares traded.
Over the past week, the price has changed by -25.42%, over one month by -36.97%, over three months by -40.33% and over the past year by -74.00%.
Neither. Based on ValueRay Fundamental Analyses, Prime Medicine Common is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -14.28 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRME as of March 2025 is 0.98. This means that PRME is currently overvalued and has a potential downside of -45.25%.
Prime Medicine Common has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy PRME.
- Strong Buy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PRME Prime Medicine Common will be worth about 1.1 in March 2026. The stock is currently trading at 1.79. This means that the stock has a potential downside of -36.31%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 12.9 | 621.2% |
| Analysts Target Price | 13.7 | 665.4% |
| ValueRay Target Price | 1.1 | -36.3% |